We are advising Esco Lifesciences on the spinoff

Davis Polk is advising Esco Lifesciences in connection with the spinoff of its CRDMO-certified agriculture business, Esco Aster, which became a fully independent business after the spinoff.

Esco Lifesciences provides enabling technologies, products and services to the life sciences and healthcare industries, supporting academic research and scientific discoveries, clinical practice, as well as biopharmaceutical R&D and manufacturing. Headquartered in Singapore, Esco Lifesciences has an extensive sales network in over 100 countries, direct sales and service offices in over 20 countries, eight manufacturing and R&D hubs in the United States, Europe, the United Kingdom, China, Singapore and over 1,300 employees worldwide.

Esco Aster is a vertically integrated contract research, development and manufacturing organization (CRDMO) founded and deeply rooted by scientists enabling fellow scientists to translate their benchwork into life-saving diagnostics, medicines, therapies, cosmeceuticals and cellular agriculture at affordable prices for self-sufficiency.

The Davis Polk corporate team includes partners Yang Chu and Howard Zhang and registered foreign lawyers Michael Zhuoran Xu and Beiming Liu. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.

Copy link to share post